

1. Record Nr.	UNISA990001808420203316
Autore	MAZZONI, Guido <1912-2001>
Titolo	La caccia da salvare : scritti e discorsi sulla legge stralcio / Guido Mazzoni
Pubbl/distr/stampa	Firenze, : Sansoni, 1970
Descrizione fisica	166 p. ; 21 cm
Collana	Caccia e pesca
Disciplina	346.45046954
Soggetti	Caccia - Legislazione - Italia
Collocazione	XXIV.3.P 42 (IX A 320)
Lingua di pubblicazione	Italiano
Formato	Materiale a stampa
Livello bibliografico	Monografia
2. Record Nr.	UNINA9910689470703321
Titolo	CFTC report entitled "A new regulatory framework" : hearing before the Committee on Agriculture, Nutrition, and Forestry, United States Senate, Subcommittee on Research, Nutrition and General Legislation, One Hundred Sixth Congress, second session on CFTC report entitled "A new regulatory framework", March 20, 2000
Descrizione fisica	1 online resource (iv, 108 p.)
Soggetti	Derivative securities - Law and legislation - United States Commodity exchanges - Law and legislation - United States Commodity futures - United States
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia

3. Record Nr.	UNINA9910557359303321
Autore	L. Pouliquen Daniel
Titolo	Malignant Mesothelioma
Pubbl/distr/stampa	Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021
Descrizione fisica	1 online resource (328 p.)
Soggetti	Medicine
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Sommario/riassunto	<p>Malignant mesothelioma (MM) is a rare and aggressive cancer, related to chronic inflammation and oxidative stress caused mainly by exposure to asbestos. Although this mineral has been banned for decades in many countries, epidemiologists predict the MM epidemic will last past 2040, raising many concerns in public health given its late diagnosis, dismal prognosis, and lack of current efficient therapies. To deal with this situation, important breakthroughs have recently been made in the understanding of MM's complex biology and the carcinogenic process of the different patterns of the disease. Examples of these include the development of new biomarkers and the deciphering of gene-environment interactions, molecular mechanisms of invasiveness, deregulated pathways, altered expression of miRNAs, DNA damage repair, or metabolic profile. From now on, MM's aggressive and chemoresistant character appears linked to a polyclonal malignancy, and heterogeneity in molecular alterations. Given these improvements, new therapeutic targets are being explored to solve the double challenge faced by clinicians. The first is to reduce tumor development and its wasting consequences as soon as possible, without resistance and with limited toxicity. The second is to stimulate the recognition of tumor cells by the induction of a specific immune response. This Special Issue will highlight all these aspects.</p>